| Sep 16 |
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
|
| Sep 6 |
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
|
| Sep 5 |
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
|
| Sep 4 |
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
|
| Sep 4 |
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
|
| Sep 4 |
High-dose Spinraza meets study goal; Top Dyne executives exit
|
| Sep 3 |
Denali to file for FDA accelerated approval of DNL310 in early 2025
|
| Sep 3 |
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
|
| Aug 26 |
Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years
|
| Aug 20 |
Denali Therapeutics Continues To Have Plenty Of Moving Parts
|
